Implications of the Iressa® Survival Evaluation in Lung Cancer Trial and the future of gefitinib

Research output: Contribution to journal › Editorial › peer-review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{1872ea61133b40d48b95ab9135b51fa5,

title = "Implications of the Iressa{\textregistered} Survival Evaluation in Lung Cancer Trial and the future of gefitinib",

author = "Chandra Belani and Sakkaraiappan Ramalingam",

year = "2005",

month = jan,

language = "English (US)",

volume = "6",

pages = "203--204",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Implications of the Iressa® Survival Evaluation in Lung Cancer Trial and the future of gefitinib

AU - Belani, Chandra

AU - Ramalingam, Sakkaraiappan

PY - 2005/1

Y1 - 2005/1

UR - https://www.scopus.com/pages/publications/14644422191

UR - https://www.scopus.com/pages/publications/14644422191#tab=citedBy

M3 - Editorial

C2 - 15694010

AN - SCOPUS:14644422191

SN - 1525-7304

VL - 6

SP - 203

EP - 204

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 4

ER -